Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis

The emergence of clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin has prompted a search for new and novel therapeutic agents active against S. aureus. Lysostaphin, a peptidase produced by Staphylococcus simulans, specifically cleaves the glyc...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Climo, Michael W., Patron, Roberto L., Goldstein, Beth P., Archer, Gordon L.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1998
Assuntos:	Experimental Therapeutics
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC105603/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9624475/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.42.6.1355
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!